Akebia Therapeutics, Inc. (AKBA)

1.3700 +0.0700 (+5.38%) 收市：04:00PM EDT

Akebia Therapeutics, Inc.

245 First Street
Suite 1400
Cambridge, MA 02142
United States
617 871 2098
https://www.akebia.com

版塊: Healthcare
行業: Biotechnology
全職員工: 167

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. John P. Butler MBA	CEO, President, Interim Principal Financial Officer & Director	1.81M	無	1964
Mr. Michel Dahan	Senior VP & COO	1.02M	無	1979
Ms. Nicole R. Hadas J.D.	Senior VP, Chief Legal Officer & Secretary	933.3k	無	1973
Dr. Steven Keith Burke M.D.	Senior VP of Research & Development and Chief Medical Officer	937.39k	無	1961
Mr. Richard C. Malabre	Chief Accounting Officer	無	無	1961
Ms. Kimberly Garko	Senior VP & Chief Technical Officer	無	無	無
Tracey Vetterick	Vice President of Portfolio Strategy & Corporate Administration	無	無	無
Mercedes Carrasco	Senior Director of Investor & Corporate Communications	無	無	無
Ms. Meredith Bowman	Senior VP & Chief People Officer	無	無	無
Ms. Carolyn Rucci	Senior Vice President of Legal & General Counsel	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，Akebia Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：9；董事會：6；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。